Atlas Molecular Pharma to Begin Dosing First Patients in Phase 2 Trial of ATL-001 for Cong... 03/09/2026 Healthcare Rare diseases Innovative drugs Atlas Molecular Pharma, a Basque biotech developing pharmacological chaperone therapies for rare diseases, announces... Partners - Atlas Molecular Pharma
Almirall and Certest Biotec enter strategic research collaboration and licensing agreement 31/08/2026 Healthcare Rare diseases Innovative drugs Almirall and Certest Biotec, S.L., through its pharmaceutical division, Certest Pharma, have entered into a strategic... Partners - CERTEST BIOTEC
An Opportunity to Transform Research on Rare Diseases in Europe 24/07/2026 Healthcare Rare diseases Personalized medicine Between 27 and 36 million people in the European Union live with one of the 6,000 to 8,000 known rare diseases. Partners - GENESIS Biomed
ORYZON announces U.S. patent grant for vafidemstat in borderline personality disorder (BP... 08/07/2026 Healthcare Rare diseases Innovative drugs Granted claims cover the use of vafidemstat for treating non-aggressive symptoms of BPD. Partners - Oryzon Genomics
World ALS Day | “ALS research is currently going through a particularly promising moment” 21/06/2026 Healthcare Rare diseases Innovative drugs Personalized medicine We interview Alfonso de Egaña Barrenechea, CEO of Molefy Pharma, a company developing AP-2, an innovative molecule... AseBio - MOLEFY PHARMA
Research on the TDP-43 protein opens new therapeutic avenues for ALS 20/06/2026 Biotechnology is driving new strategies to combat ALS, including research on the TDP-43 protein, a key target involved... AseBio
Shilpa Biocare Invests in Gate2Brain to Advance G2B-002, an Innovative Brain Cancer Thera... 16/06/2026 Healthcare Rare diseases Innovative drugs Gate2Brain signs a strategic partnership with Shilpa Biocare, including a €7 million investment for a 30.4% equity stake... Partners - Gate2Brain
Miramoon Pharma Wins Second Prize at ARVO 2026 Eye Pitch Competition 27/05/2026 Healthcare Rare diseases Advanced therapies The startup receives $15,000 award for its innovative MP-004 therapy targeting retinitis pigmentosa. Partners - Miramoon Pharma
U.S. announces pharmaceutical tariffs under Section 232: what it means for biotech compani... 10/04/2026 Healthcare Drug discovery Rare diseases Innovative drugs Industrial biotechnology International At AseBio, we believe this Executive Order creates uncertainty for the European biotechnology sector—especially for... AseBio
AseBio promotes in Brussels the vision of the Spanish biotechnology sector on the Biotech ... 23/03/2026 Healthcare Rare diseases Innovative drugs Advanced therapies EU projects Our Director General, Ion Arocena, participated in the latest meeting of the MEP Interest Group “EU Biotech and Life... AseBio
